KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to $267.7 million.

  • Alnylam Pharmaceuticals' Cost of Revenue rose 16081.4% to $267.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $677.2 million, marking a year-over-year increase of 12092.57%. This contributed to the annual value of $677.2 million for FY2025, which is 12092.57% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Cost of Revenue stood at $267.7 million for Q4 2025, which was up 16081.4% from $197.2 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Cost of Revenue registered a high of $267.7 million during Q4 2025, and its lowest value of $23.0 million during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $60.9 million (2024), whereas its average is $75.4 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Cost of Revenue plummeted by 1070.54% in 2024, and later soared by 16081.4% in 2025.
  • Alnylam Pharmaceuticals' Cost of Revenue (Quarter) stood at $33.6 million in 2021, then surged by 37.27% to $46.2 million in 2022, then skyrocketed by 55.88% to $72.0 million in 2023, then surged by 42.62% to $102.6 million in 2024, then surged by 160.81% to $267.7 million in 2025.
  • Its Cost of Revenue stands at $267.7 million for Q4 2025, versus $197.2 million for Q3 2025 and $142.0 million for Q2 2025.